Aptamer Group and WuXi AppTec Research Service Division collaborate to identify new Optimer™ enabled therapeutics

Aptamer Group Limited, the developer of Optimer™ therapeutics and diagnostics, and WuXi AppTec Research Service Division, an integrated chemistry and biology research platform, today announce a research collaboration to identify new Optimer™-enabled therapeutics.

The collaboration will aim to identify Optimers for use as Optimer-drug conjugates for targeted delivery of diverse payloads to new cellular targets. Achieving targeted delivery of drugs to specific tissues and organs can increase the therapeutic dose at site of action to increase therapeutic efficacy, and reduce off-target effects to improve patient tolerability. This remains a major translational challenge for many new precision medicines.

As part of the agreement, Aptamer Group will develop Optimers to specific disease biomarkers and supply them to WuXi AppTec Research Service Division for further evaluation as potential delivery vehicles.

Aptamer Group is pleased to be developing novel Optimers for use as delivery vehicles in partnership with WuXi AppTec Research Service Division. This work further validates our Optimer platform as a flexible solution that can be integrated into therapeutic pipelines to potentially accelerate development and deliver important, life-changing therapeutics for patients with hard to treat diseases.”

Dr Arron Tolley, Chief Executive Officer, Aptamer Group

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Aptamer Group. (2021, July 23). Aptamer Group and WuXi AppTec Research Service Division collaborate to identify new Optimer™ enabled therapeutics. News-Medical. Retrieved on April 21, 2024 from https://www.news-medical.net/news/20210723/Aptamer-Group-and-WuXi-AppTec-Research-Service-Division-collaborate-to-identify-new-Optimere284a2-enabled-therapeutics.aspx.

  • MLA

    Aptamer Group. "Aptamer Group and WuXi AppTec Research Service Division collaborate to identify new Optimer™ enabled therapeutics". News-Medical. 21 April 2024. <https://www.news-medical.net/news/20210723/Aptamer-Group-and-WuXi-AppTec-Research-Service-Division-collaborate-to-identify-new-Optimere284a2-enabled-therapeutics.aspx>.

  • Chicago

    Aptamer Group. "Aptamer Group and WuXi AppTec Research Service Division collaborate to identify new Optimer™ enabled therapeutics". News-Medical. https://www.news-medical.net/news/20210723/Aptamer-Group-and-WuXi-AppTec-Research-Service-Division-collaborate-to-identify-new-Optimere284a2-enabled-therapeutics.aspx. (accessed April 21, 2024).

  • Harvard

    Aptamer Group. 2021. Aptamer Group and WuXi AppTec Research Service Division collaborate to identify new Optimer™ enabled therapeutics. News-Medical, viewed 21 April 2024, https://www.news-medical.net/news/20210723/Aptamer-Group-and-WuXi-AppTec-Research-Service-Division-collaborate-to-identify-new-Optimere284a2-enabled-therapeutics.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Aptamer Group and Bio-Works Technologies partner to enable improved solutions for gene therapy manufacturing